医学
危险系数
淋巴血管侵犯
乳腺癌
磁共振成像
比例危险模型
水肿
放射科
乳房磁振造影
阶段(地层学)
癌症
内科学
乳腺摄影术
置信区间
转移
古生物学
生物
作者
Hyejin Cheon,Hye Jung Kim,Tae Hun Kim,Hunkyu Ryeom,Jongmin Lee,Gab Chul Kim,Jin‐Sung Yuk,Won Hwa Kim
出处
期刊:Radiology
[Radiological Society of North America]
日期:2018-01-09
卷期号:287 (1): 68-75
被引量:132
标识
DOI:10.1148/radiol.2017171157
摘要
Purpose To determine the prognostic value of peritumoral edema identified at preoperative breast magnetic resonance (MR) imaging for disease recurrence in patients with invasive breast cancer. Materials and Methods Between January 2011 and December 2012, 353 women (median age, 49 years; range, 27–77 years) with invasive breast cancer who had undergone preoperative MR imaging and mastectomy or breast-conserving surgery were identified. Two radiologists independently reviewed peritumoral edema on the basis of the degree of the signal intensity surrounding the tumor on T2-weighted images. The association of disease recurrence with peritumoral edema and clinical-pathologic features was assessed by using the multivariate Cox proportional hazards model and the integrated discrimination improvement (IDI) and continuous net reclassification improvement (NRI) indexes. Results Twenty-four patients (6.8%) had disease recurrence after 27.2 months of median follow-up. At multivariate analysis, higher N stage (hazard ratio = 4.84, P = .002) and the presence of lymphovascular invasion (hazard ratio = 2.48, P = .044) and peritumoral edema (hazard ratio = 2.77, P = .022) were independent factors associated with disease recurrence. IDI and continuous NRI showed significant improvement in the accuracy of the association with disease recurrence when peritumoral edema was added to established clinical-pathologic features (IDI = 0.061, P < .001; continuous NRI = 0.334, P = .012). Conclusion Peritumoral edema identified at preoperative MR imaging is independently associated with disease recurrence. Peritumoral edema assessment may provide better prognostication in patients with invasive breast cancer. © RSNA, 2018
科研通智能强力驱动
Strongly Powered by AbleSci AI